What is Efinopegdutide?
A long-acting GLP-1/glucagon dual agonist from Merck studied for MASH.
Efinopegdutide in the library · · Human Trials · What are peptides?
7 registered trials · 1 indexed papers · 2 human / 0 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Efinopegdutide is described as a once-weekly dual agonist attached to an antibody fragment for long action.
Mechanism (as described)
- Glucagon activity targets liver fat; GLP-1 activity reduces appetite.
Evidence (as described)
- A phase 2a trial reported greater liver-fat reduction than semaglutide in NAFLD (Romero-Gómez et al., 2023).
Status
Investigational.
Registered human trials (7)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Phase 2 | completed | 2024 | 85 |
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | Phase 2 | completed | 2024 | 124 |
| A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) | Phase 1 | completed | 2024 | 48 |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Phase 2 | completed | 2023 | 381 |
| A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) | Phase 1 | completed | 2023 | 22 |
| A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) | Phase 1 | completed | 2022 | 56 |
| A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Phase 2 | completed | 2021 | 145 |
Peer-reviewed studies (1)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease | Romero-Gómez M et al. | Journal of hepatology | 2023 | Randomized Controlled Trial |
More cited research
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis (2026, human RCT)
Conditions researched
Related compounds
- Cotadutide
- Pemvidutide
- ACTH (Corticotropin)
- ANP (Atrial Natriuretic Peptide)
- Alpha-MSH
- Angiotensin II
- CGRP (Calcitonin Gene-Related Peptide)
- CagriSema (Cagrilintide + Semaglutide)
- Calcitonin
- Carnosine
FAQ
What is Efinopegdutide?
A long-acting GLP-1/glucagon dual agonist from Merck studied for MASH.
How many registered human trials study Efinopegdutide?
The PeptideWhiz trial index lists 7 registered trials for Efinopegdutide, the most recent from 2024.
How much published research exists on Efinopegdutide?
The PeptideWhiz paper index links 1 PubMed paper to Efinopegdutide; by study type, 2 human and 0 animal studies.
Which conditions is Efinopegdutide researched for?
Fatty liver & elevated liver enzymes.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).